M. E. Lacouture et al. – Most dermatologic events (DEs) in lapatinib-treated patients present early, are mild to moderate in severity, and infrequently require dose modification or treatment interruption. Lapatinib-associated DEs appear to differ clinically from those associated with EGFR TKIs in both frequency and severity. Methods
Aim was to characterize the DEs in cancer pts treated with lapatinib
9 clinical trials of metastatic cancer were included in this analysis
Lapatinib was administered at doses ranging from 1000-1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)
Pts not treated with lapatinib comprised the control group
DEs were characterized based on type, time to onset, severity, duration, and required interventions
Results
58% of pts treated with lapatinib monotherapy, 74% treated with lapatinib plus paclitaxel or capecitabine, and 53% in the control group developed DEs
Among pts receiving lapatinib monotherapy, 55% experienced grade 1/2 DEs, 3% had grade 3 DEs, and no grade 4 DEs were observed
The most common DE was rash (43%); all other events occurred in ≤8% of pts
Most DEs developed between d1 and 14 of starting treatment, with a median duration of 29 d
3% of DEs led to lapatinib dose reduction, 7% resulted in dose interruption, and 1% led to drug discontinuation
See all
